vs
Side-by-side financial comparison of Journey Medical Corp (DERM) and Ponce Financial Group, Inc. (PDLB). Click either name above to swap in a different company.
Ponce Financial Group, Inc. is the larger business by last-quarter revenue ($31.4M vs $16.1M, roughly 2.0× Journey Medical Corp). Ponce Financial Group, Inc. runs the higher net margin — 36.3% vs -7.8%, a 44.0% gap on every dollar of revenue. On growth, Ponce Financial Group, Inc. posted the faster year-over-year revenue change (37.6% vs 27.3%). Over the past eight quarters, Ponce Financial Group, Inc.'s revenue compounded faster (23.7% CAGR vs 11.0%).
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
Ponce Financial Group, Inc. is a U.S.-based financial holding company operating Ponce Bank as its core subsidiary. It serves multicultural, immigrant and low-to-moderate income communities in the New York metro area, offering retail and commercial banking products including deposits, mortgages, small business financing and personal credit.
DERM vs PDLB — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.1M | $31.4M |
| Net Profit | $-1.2M | $10.1M |
| Gross Margin | — | — |
| Operating Margin | -2.8% | 43.6% |
| Net Margin | -7.8% | 36.3% |
| Revenue YoY | 27.3% | 37.6% |
| Net Profit YoY | -182.0% | 245.6% |
| EPS (diluted) | $-0.04 | $0.43 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.1M | $31.4M | ||
| Q3 25 | $17.0M | $26.7M | ||
| Q2 25 | $15.0M | $26.5M | ||
| Q1 25 | $13.1M | $24.6M | ||
| Q4 24 | $12.6M | $22.8M | ||
| Q3 24 | $14.6M | $20.2M | ||
| Q2 24 | $14.9M | $20.2M | ||
| Q1 24 | $13.0M | $20.5M |
| Q4 25 | $-1.2M | $10.1M | ||
| Q3 25 | $-2.3M | $6.5M | ||
| Q2 25 | $-3.8M | $6.1M | ||
| Q1 25 | $-4.1M | $6.0M | ||
| Q4 24 | $1.5M | $2.9M | ||
| Q3 24 | $-2.4M | $2.4M | ||
| Q2 24 | $-3.4M | $3.2M | ||
| Q1 24 | $-10.4M | $2.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 82.3% | — | ||
| Q3 24 | 63.9% | — | ||
| Q2 24 | 56.0% | — | ||
| Q1 24 | 47.7% | — |
| Q4 25 | -2.8% | 43.6% | ||
| Q3 25 | -9.0% | 32.8% | ||
| Q2 25 | -19.2% | 30.2% | ||
| Q1 25 | -25.3% | 32.5% | ||
| Q4 24 | 17.7% | 19.6% | ||
| Q3 24 | -19.8% | 15.2% | ||
| Q2 24 | -19.7% | 21.8% | ||
| Q1 24 | -77.4% | 18.3% |
| Q4 25 | -7.8% | 36.3% | ||
| Q3 25 | -13.6% | 24.3% | ||
| Q2 25 | -25.3% | 23.0% | ||
| Q1 25 | -31.0% | 24.2% | ||
| Q4 24 | 12.1% | 14.1% | ||
| Q3 24 | -16.3% | 12.1% | ||
| Q2 24 | -22.6% | 15.8% | ||
| Q1 24 | -80.1% | 11.8% |
| Q4 25 | $-0.04 | $0.43 | ||
| Q3 25 | $-0.09 | $0.27 | ||
| Q2 25 | $-0.16 | $0.25 | ||
| Q1 25 | $-0.18 | $0.25 | ||
| Q4 24 | $0.10 | $0.11 | ||
| Q3 24 | $-0.12 | $0.10 | ||
| Q2 24 | $-0.17 | $0.14 | ||
| Q1 24 | $-0.53 | $0.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $24.1M | $126.2M |
| Total DebtLower is stronger | $25.3M | $596.1M |
| Stockholders' EquityBook value | $31.9M | $541.5M |
| Total Assets | $94.6M | $3.2B |
| Debt / EquityLower = less leverage | 0.79× | 1.10× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $24.1M | $126.2M | ||
| Q3 25 | $24.9M | $146.6M | ||
| Q2 25 | $20.3M | $126.6M | ||
| Q1 25 | $21.1M | $129.9M | ||
| Q4 24 | $20.3M | $139.8M | ||
| Q3 24 | $22.5M | $155.8M | ||
| Q2 24 | $23.9M | $103.2M | ||
| Q1 24 | $24.1M | $134.7M |
| Q4 25 | $25.3M | $596.1M | ||
| Q3 25 | $25.2M | $521.1M | ||
| Q2 25 | $25.1M | $536.1M | ||
| Q1 25 | $25.0M | $521.1M | ||
| Q4 24 | $24.9M | $596.1M | ||
| Q3 24 | $19.8M | $580.4M | ||
| Q2 24 | $19.7M | $680.4M | ||
| Q1 24 | $14.7M | $680.4M |
| Q4 25 | $31.9M | $541.5M | ||
| Q3 25 | $25.9M | $529.8M | ||
| Q2 25 | $19.2M | $521.1M | ||
| Q1 25 | $21.5M | $513.9M | ||
| Q4 24 | $20.1M | $505.5M | ||
| Q3 24 | $10.9M | $504.6M | ||
| Q2 24 | $11.3M | $497.7M | ||
| Q1 24 | $13.0M | $493.7M |
| Q4 25 | $94.6M | $3.2B | ||
| Q3 25 | $85.2M | $3.2B | ||
| Q2 25 | $81.2M | $3.2B | ||
| Q1 25 | $85.0M | $3.1B | ||
| Q4 24 | $80.2M | $3.0B | ||
| Q3 24 | $64.0M | $3.0B | ||
| Q2 24 | $65.2M | $2.8B | ||
| Q1 24 | $66.6M | $2.8B |
| Q4 25 | 0.79× | 1.10× | ||
| Q3 25 | 0.97× | 0.98× | ||
| Q2 25 | 1.30× | 1.03× | ||
| Q1 25 | 1.16× | 1.01× | ||
| Q4 24 | 1.24× | 1.18× | ||
| Q3 24 | 1.81× | 1.15× | ||
| Q2 24 | 1.75× | 1.37× | ||
| Q1 24 | 1.13× | 1.38× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.3M | $55.6M |
| Free Cash FlowOCF − Capex | — | $54.6M |
| FCF MarginFCF / Revenue | — | 173.9% |
| Capex IntensityCapex / Revenue | — | 3.1% |
| Cash ConversionOCF / Net Profit | — | 5.48× |
| TTM Free Cash FlowTrailing 4 quarters | — | $74.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.3M | $55.6M | ||
| Q3 25 | $-2.4M | $1.4M | ||
| Q2 25 | $-942.0K | $6.2M | ||
| Q1 25 | $-2.8M | $13.1M | ||
| Q4 24 | $2.2M | $7.2M | ||
| Q3 24 | $-1.2M | $-14.6M | ||
| Q2 24 | $-5.2M | $-2.6M | ||
| Q1 24 | $-5.0M | $1.5M |
| Q4 25 | — | $54.6M | ||
| Q3 25 | — | $786.0K | ||
| Q2 25 | — | $5.9M | ||
| Q1 25 | — | $12.9M | ||
| Q4 24 | — | $4.5M | ||
| Q3 24 | — | $-15.0M | ||
| Q2 24 | — | $-2.6M | ||
| Q1 24 | — | $-315.0K |
| Q4 25 | — | 173.9% | ||
| Q3 25 | — | 2.9% | ||
| Q2 25 | — | 22.4% | ||
| Q1 25 | — | 52.6% | ||
| Q4 24 | — | 19.7% | ||
| Q3 24 | — | -74.1% | ||
| Q2 24 | — | -13.0% | ||
| Q1 24 | — | -1.5% |
| Q4 25 | — | 3.1% | ||
| Q3 25 | — | 2.3% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 0.6% | ||
| Q4 24 | — | 11.9% | ||
| Q3 24 | — | 2.0% | ||
| Q2 24 | — | 0.3% | ||
| Q1 24 | — | 8.7% |
| Q4 25 | — | 5.48× | ||
| Q3 25 | — | 0.21× | ||
| Q2 25 | — | 1.01× | ||
| Q1 25 | — | 2.20× | ||
| Q4 24 | 1.46× | 2.46× | ||
| Q3 24 | — | -5.99× | ||
| Q2 24 | — | -0.80× | ||
| Q1 24 | — | 0.61× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
PDLB
Segment breakdown not available.
